Funded Biotechnology Startups in London
London's biotechnology sector shows sustained deal flow across a roughly 33-month window, with round sizes ranging from Carbon Cell's $150K pre-seed in May…
London's biotechnology sector shows sustained deal flow across a roughly 33-month window, with round sizes ranging from Carbon Cell's $150K pre-seed in May 2024 to Verdiva Bio's $411M Series A in January 2025 — the largest single close among the 50 most recent. Series B activity concentrates heavily in 2024: Purespring Therapeutics ($105M, October), Vicebio ($100M, September), and Pheon Therapeutics ($120M, May) all closed within a six-month span. Series A rounds are also prominent, with Myricx Bio ($115M, July 2024) and LOQUS23 Therapeutics ($47M, October 2024) among the larger examples.
Early-stage closes are present but less frequent: six Seed rounds and two Pre-Seed rounds appear in the dataset, including BoobyBiome ($3M, September 2025) and Samphire Neuroscience ($5M, June 2025). At least six rounds — MYndspan, Lindus Health, xterna, BugBiome, Ellipses Pharma, and Autolomous — carry undisclosed deal sizes, indicating the disclosed totals underrepresent actual volume.
Most recent rounds
50 shownRelated listings
Frequently asked
What are the largest disclosed rounds among London biotech companies in this dataset?
Verdiva Bio leads at $411M (Series A, January 2025), followed by Autolus at $150M (December 2022), Pheon Therapeutics at $120M (Series B, May 2024), Myricx Bio at $115M (Series A, July 2024), Purespring Therapeutics at $105M (Series B, October 2024), and Vicebio at $100M (Series B, September 2024).
Which funding stages appear most frequently in recent London biotech rounds?
Series Unknown is the most common label, appearing on 26 of the 50 rounds and spanning from $330K (HemoGenyx) to $150M (Autolus). Series A is next with ten closes, followed by Seed with six, Series B with five, and Pre-Seed with two.
How many rounds have undisclosed amounts, and which companies are they?
Six rounds list undisclosed amounts: MYndspan (April 2025), Lindus Health (April 2025), xterna (December 2024), BugBiome (February 2024), Ellipses Pharma (July 2023), and Autolomous (June 2023). All six carry a Series Unknown stage designation.
Which biotech sub-sectors are drawing the largest individual checks among London companies?
Cell and gene therapy accounts for several of the largest closes — Pheon Therapeutics ($120M Series B), Purespring Therapeutics ($105M Series B), and Autolus ($150M). Therapeutic antibody and immunology platforms are also prominent, with Myricx Bio ($115M Series A), LOQUS23 Therapeutics ($47M Series A), and Alchemab Therapeutics ($32M Series A) all closing in 2024 or 2025. Microbiome and neuroscience companies appear at earlier stages.
How does 2025 London biotech funding activity compare to 2024 in this dataset?
The dataset shows 13 rounds closing in 2025 through September, compared to 20 rounds across all of 2024. The 2025 cohort includes Verdiva Bio's $411M Series A — the largest single close in the full 50-row dataset — alongside Alchemab Therapeutics ($32M Series A), Epoch Biodesign ($18M Series A), and PassEntry ($7M).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.